These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 17599817

  • 1. The renal clearance of dextran sulfate decreases in puromycin aminonucleoside-induced glomerulosclerosis: a puzzle observation.
    Santos AM, Pomin VH, Stelling MP, Guimarães MA, Cardoso LR, Mourão PA.
    Clin Chim Acta; 2007 Aug; 383(1-2):116-25. PubMed ID: 17599817
    [Abstract] [Full Text] [Related]

  • 2. Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside.
    Grond J, Weening JJ, Elema JD.
    Lab Invest; 1984 Sep; 51(3):277-85. PubMed ID: 6471809
    [Abstract] [Full Text] [Related]

  • 3. Glomerular basement membrane heparan sulfate glycosaminoglycan in aminonucleoside of puromycin nephrosis.
    Garin EH, Shirey AJ.
    Child Nephrol Urol; 1984 Sep; 9(3):121-6. PubMed ID: 2978121
    [Abstract] [Full Text] [Related]

  • 4. Podocyte architecture in puromycin aminonucleoside-treated rats administered tungsten or allopurinol.
    Ricardo SD, Bertram JF, Ryan GB.
    Exp Nephrol; 1995 Sep; 3(5):270-9. PubMed ID: 7583048
    [Abstract] [Full Text] [Related]

  • 5. Alterations in the charge and size selectivity barrier of the glomerular filter in aminonucleoside nephrosis in rats.
    Olson JL, Rennke HG, Venkatachalam MA.
    Lab Invest; 1981 Mar; 44(3):271-9. PubMed ID: 7464051
    [Abstract] [Full Text] [Related]

  • 6. Altered expression of NDST-1 messenger RNA in puromycin aminonucleoside nephrosis.
    Nakayama K, Natori Y, Sato T, Kimura T, Sugiura A, Sato H, Saito T, Ito S, Natori Y.
    J Lab Clin Med; 2004 Feb; 143(2):106-14. PubMed ID: 14966466
    [Abstract] [Full Text] [Related]

  • 7. Unilateral renal disease in the rat. I. Clinical, morphologic, and glomerular mesangial functional features of the experimental model produced by renal perfusion with aminonucleoside.
    Hoyer JR, Mauer SM, Michael AF.
    J Lab Clin Med; 1975 May; 85(5):756-68. PubMed ID: 1091713
    [Abstract] [Full Text] [Related]

  • 8. Ameliorative effects of dietary protein restriction in chronic aminonucleoside nephrosis.
    Diamond JR, Karnovsky MJ.
    J Lab Clin Med; 1987 May; 109(5):538-44. PubMed ID: 3572200
    [Abstract] [Full Text] [Related]

  • 9. Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
    Zheng Y, Shirato I, Maeda A, Kobayashi N, Liao J, Shou I, Fukui M, Tomino Y.
    J Nephrol; 2002 May; 15(1):36-41. PubMed ID: 11936424
    [Abstract] [Full Text] [Related]

  • 10. Glomerular processing of dextran sulfate during transcapillary transport.
    Vyas SV, Burne MJ, Pratt LM, Comper WD.
    Arch Biochem Biophys; 1996 Aug 15; 332(2):205-12. PubMed ID: 8806727
    [Abstract] [Full Text] [Related]

  • 11. Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
    Yamashita J, Nakajima K, Ohno Y, Kaneshiro Y, Matsuo T, Tanaka H, Kaneko K.
    Eur J Pharmacol; 2008 Jul 28; 589(1-3):239-44. PubMed ID: 18541230
    [Abstract] [Full Text] [Related]

  • 12. Beneficial effects of orosomucoid on the glomerular barrier in puromycin aminonucleoside-induced nephrosis.
    Hjalmarsson C, Lidell ME, Haraldsson B.
    Nephrol Dial Transplant; 2006 May 28; 21(5):1223-30. PubMed ID: 16410268
    [Abstract] [Full Text] [Related]

  • 13. Urinary kallikrein in experimental renal disease.
    Glasser RJ, Michael AF.
    Lab Invest; 1976 Jun 28; 34(6):616-22. PubMed ID: 933467
    [Abstract] [Full Text] [Related]

  • 14. Experimental model of focal sclerosis. I. Relationship to protein excretion in aminonucleoside nephrosis.
    Glasser RJ, Velosa JA, Michael AF.
    Lab Invest; 1977 May 28; 36(5):519-26. PubMed ID: 865079
    [Abstract] [Full Text] [Related]

  • 15. Renal purine efflux and xanthine oxidase activity during experimental nephrosis in rats: difference between puromycin aminonucleoside and adriamycin nephrosis.
    Ginevri F, Gusmano R, Oleggini R, Acerbo S, Bertelli R, Perfumo F, Cercignani G, Allegrini S, D'Allegri F, Ghiggeri G.
    Clin Sci (Lond); 1990 Mar 28; 78(3):283-93. PubMed ID: 2156648
    [Abstract] [Full Text] [Related]

  • 16. Ultrastructural study on nephrin expression in experimental puromycin aminonucleoside nephrosis.
    Lee YK, Kwon T, Kim DJ, Huh W, Kim YG, Oh HY, Kawachi H.
    Nephrol Dial Transplant; 2004 Dec 28; 19(12):2981-6. PubMed ID: 15385636
    [Abstract] [Full Text] [Related]

  • 17. In situ hybridization of type I collagen mRNA in puromycin aminonucleoside-induced glomerulosclerosis.
    Osada S, Ebihara I, Nakamura T, Fukui M, Tomino Y, Koide H.
    Exp Nephrol; 1995 Dec 28; 3(1):40-8. PubMed ID: 7712142
    [Abstract] [Full Text] [Related]

  • 18. Furosemide disposition in normal and proteinuric rats: urinary drug-protein binding as a determinant of drug excretion.
    Green TP, Mirkin BL.
    J Pharmacol Exp Ther; 1981 Jul 28; 218(1):122-7. PubMed ID: 7241373
    [Abstract] [Full Text] [Related]

  • 19. Increased glomerular and extracellular malondialdehyde levels in patients and rats with focal segmental glomerulosclerosis.
    Kuo HT, Kuo MC, Chiu YW, Chang JM, Guh JY, Chen HC.
    Eur J Clin Invest; 2005 Apr 28; 35(4):245-50. PubMed ID: 15816993
    [Abstract] [Full Text] [Related]

  • 20. Morphologic, molecular and hemodynamic cardiac alterations in a model of nephropathy induced by puromycin aminonucleoside.
    Moreira-Rodrigues M, Roncon-Albuquerque R, Henriques-Coelho T, Sampaio-Maia B, Leite-Moreira A, Pestana M.
    Rev Port Cardiol; 2006 May 28; 25(5):509-18. PubMed ID: 16910158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.